Olr773 inhibitors represent a fascinating class of chemical compounds that specifically interact with the Olr773 receptor, a type of olfactory receptor protein. These inhibitors are typically small molecules designed to bind to the receptor and prevent its normal function, thereby modulating the receptor's activity in response to olfactory stimuli. The Olr773 receptor, like other olfactory receptors, is part of a large family of G protein-coupled receptors (GPCRs) that play a crucial role in the detection of odorants and the initiation of olfactory signal transduction. Inhibitors targeting Olr773 can vary widely in their chemical structure, ranging from simple organic molecules to more complex compounds with multiple functional groups that confer specificity and affinity towards the receptor.
The study of Olr773 inhibitors involves a detailed understanding of the receptor's structure, which is typically explored using techniques such as X-ray crystallography, NMR spectroscopy, and molecular modeling. These inhibitors are often designed to fit precisely into the binding pocket of the Olr773 receptor, a process that requires extensive computational docking studies and structure-activity relationship (SAR) analyses. By examining how different modifications to the inhibitor's structure affect its binding affinity and selectivity, researchers can fine-tune these compounds to achieve the desired inhibitory effect. Furthermore, the synthesis of Olr773 inhibitors involves sophisticated organic chemistry techniques, including the use of protecting groups, selective functional group transformations, and chiral resolution. The development of these inhibitors not only enhances our understanding of olfactory receptor function but also provides valuable insights into the broader field of GPCR biology and the intricate mechanisms underlying olfaction.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A kinase inhibitor that could impact cell proliferation and angiogenesis pathways. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
An EGFR inhibitor, potentially affecting epidermal growth factor receptor signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A receptor tyrosine kinase inhibitor, could modulate cell growth and angiogenesis pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
A JAK1/2 inhibitor, might influence cytokine signaling and immune response. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
A kinase inhibitor, could affect VEGFR, EGFR, and RET signaling pathways. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Targets MET, VEGFR, and AXL, potentially affecting cell migration and angiogenesis. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
A BCL-2 inhibitor, could impact apoptosis and cell survival pathways. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
A CDK4/6 inhibitor, potentially impacting cell cycle progression and proliferation. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
A MEK inhibitor, could influence MAPK/ERK signaling pathways. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Targets BRAF kinase, might impact cell growth and proliferation pathways. | ||||||